Vera Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Vera Therapeutics Stock-Based Compensation Growth & History (VERA)
Vera Therapeutics's stock-based compensation was $37.9M for fiscal 2025.
View full Vera Therapeutics company overviewVera Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $37.9M | $17.1M | +82.32% |
| 2024 | 2024-12-31 | $20.8M | $9.3M | +81.00% |
| 2023 | 2023-12-31 | $11.5M | $2.6M | +29.32% |
| 2022 | 2022-12-31 | $8.9M | $5.9M | +195.05% |
| 2021 | 2021-12-31 | $3.0M | $2.7M | +809.97% |
| 2020 | 2020-12-31 | $331,000 | — | — |
Vera Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $15.9M | $6.4M | +67.47% |
| Q1 2026 | 2026-03-31 | $13.2M | $5.5M | +70.56% |
| Q4 2025 | 2025-12-31 | $11.0M | $4.7M | +76.37% |
| Q3 2025 | 2025-09-30 | $9.7M | $4.2M | +74.39% |
| Q2 2025 | 2025-06-30 | $9.5M | $4.6M | +94.38% |
| Q1 2025 | 2025-03-31 | $7.7M | $3.6M | +87.78% |
| Q4 2024 | 2024-12-31 | $6.2M | $3.0M | +93.01% |
| Q3 2024 | 2024-09-30 | $5.6M | $2.7M | +91.17% |
| Q2 2024 | 2024-06-30 | $4.9M | $2.2M | +81.69% |
| Q1 2024 | 2024-03-31 | $4.1M | $1.5M | +54.63% |
| Q4 2023 | 2023-12-31 | $3.2M | $473,000 | +17.21% |
| Q3 2023 | 2023-09-30 | $2.9M | $471,000 | +19.21% |
| Q2 2023 | 2023-06-30 | $2.7M | $657,000 | +32.44% |
| Q1 2023 | 2023-03-31 | $2.7M | $1.0M | +60.47% |
| Q4 2022 | 2022-12-31 | $2.7M | $1.8M | +185.65% |
| Q3 2022 | 2022-09-30 | $2.5M | $1.5M | +162.81% |
| Q2 2022 | 2022-06-30 | $2.0M | $1.3M | +184.01% |
| Q1 2022 | 2022-03-31 | $1.7M | $1.3M | +311.39% |
| Q4 2021 | 2021-12-31 | $962,000 | $819,000 | +572.73% |
| Q3 2021 | 2021-09-30 | $933,000 | $817,000 | +704.31% |
| Q2 2021 | 2021-06-30 | $713,000 | $702,000 | +6381.82% |
| Q1 2021 | 2021-03-31 | $404,000 | $343,000 | +562.30% |
| Q4 2020 | 2020-12-31 | $143,000 | — | — |
| Q3 2020 | 2020-09-30 | $116,000 | — | — |
| Q2 2020 | 2020-06-30 | $11,000 | — | — |
| Q1 2020 | 2020-03-31 | $61,000 | — | — |
Vera Therapeutics stock-based compensation trends
Over the last five fiscal years, Vera Therapeutics's stock-based compensation increased from $331,000 to $37.9M, a change of $37.6M. The latest reported quarter, Q2 2026, shows $15.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vera Therapeutics source filings ↗